Medical Crossfire®: Emerging Strategies to Optimize and Individualize PAH Treatment

Released On
October 31, 2019

Expires On
October 31, 2020

Media Type

Completion Time
90 minutes

Cardiology, Pulmonology, Primary Care

PAH Treatment

Scroll to the Bottom of this Information to Begin this Course

This activity is jointly provided by Purdue University College of Pharmacy and Physicians’ Education Resource®, LLC.


Supported by an educational grant from Actelion Pharmaceuticals US, Inc. and Bayer HealthCare Pharmaceuticals.

Credit Available

  • Physicians — maximum of 1.5 AMA PRA Category 1 Credit(s)
  • Nurses — maximum of 1.5 AMA PRA Category 1 Credit(s)

All other healthcare professionals completing this course will be issued a statement of participation.

Target Audience

This online educational activity is directed toward pulmonologists, cardiologists, primary care physicians, NPs, PAs, and other healthcare professionals who treat patients with PAH.

Program Overview

Pulmonary arterial hypertension (PAH) is a devastating progressive disease with a considerable burden on quality of life and eventually leads to right-sided heart failure. Advancements in drug therapy and patient care over the past 10 years have improved the morbidity and mortality rates for patients with PAH. Although new therapies have provided major improvement to quality of life in patients with PAH, there is a continual delay in diagnosis and a need to improve therapeutic selection and strategies in the mission to enhance overall patient care. During this Medical Crossfire®, expert faculty will engage in a multidisciplinary roundtable discussion and dissect cases and address best practices for recognizing, diagnosing, and treating patients with PAH.

Benefits of Participating

  • Implement strategic measures to improve identification of clinical symptoms for prompt assessment and diagnosis of PAH
  • Increase awareness of current recommendations for treatment of PAH in adults
  • Implement best practices to enhance clinical decision making when examining available treatment options for patients with PAH

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Determine the role of PAH in differential diagnosis and the appropriate classification of severity
  • Apply PAH classification and patient-specific considerations to selection of therapeutic agents for PAH
  • Evaluate the potential impact of emerging treatment data on clinical practice


Bradley A. Maron, MD

Associate Physician, Division of Cardiovascular Medicine, Brigham and Women’s Hospital
Associate Professor of Medicine, Harvard Medical School
Co-Director, Pulmonary Vascular Disease Center, Boston VA Healthcare System
Boston, MA

Paul P. Doghramji, MD, FAAFP

Attending Physician
Collegeville Family Practice
Medical Director of Health Services
Ursinus College
Collegeville, PA

Ronald J. Oudiz, MD

Director, Liu Center for Pulmonary Hypertension
LA Biomedical Research Institute at Harbor-UCLA Medical Center
Torrance, CA
Professor of Medicine, The David Geffen School of Medicine at UCLA
Los Angeles, CA


Owner and Family Nurse Practitioner
Wright & Associates Family Healthcare
Amherst and Concord, NH

Accreditation Statement

Purdue University College of Pharmacy, an equal access/equal opportunity institution, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement

Purdue University College of Pharmacy designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 1.5 Contact Hours.

Disclosures of Conflicts of Interest

Bradley A. Maron, MD

  • Consultant: Actelion

Paul P. Doghramji, MD, FAAFP

  • Consultant: Jazz Pharmaceuticals, Harmony Biopharma, Eisai Pharma; Stock/Shareholder: Pfizer

Ronald J. Oudiz, MD

  • Grant/Research Support: AADi, Actelion, GSK, Reata, United Therapeutics
  • Consultant: Actelion, Gilead, United Therapeutics
  • Speaker’s Bureau: Actelion, Gilead, United Therapeutics


  • Consultant: Merck, Pfizer and Sanofi – Vaccines; GSK – Arthritis
  • Speaker’s Bureau: Merck, Pfizer, and Sanofi – Vaccines

PER® uses a blinded peer review process. The peer reviewer discloses the following: Grant/Research Support: Actelion, UT, Bayer, Reata, Complexa, PhaseBio; Consultant: Actelion, UT, Bayer, Reata

The staff of Physicians' Education Resource®, LLC, (PER®) have no relevant financial relationships with commercial interests to disclose.

Method of Participation

Instructions for This Activity and Receiving Credit

  1. You will need to log in to participate in the activity.
  2. Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review audio files/content until you finish the presentation.
  3. At the end of the activity, “Educational Content/Videos” will be available for your reference.
  4. In order to receive a CME/CE certificate, you must complete the activity.
  5. Complete the Posttest and pass with a score of 70% or higher, complete the Evaluation, and then click on “Request for Credit.” You may immediately download a CME/CE Certificate upon completion of these steps.

Course Viewing Requirements

Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As co-providers of the activity, it is the policy of PER® and Purdue University to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME/CE activities. In compliance with ACCME and CBN guidelines, PER® and Purdue University require everyone who is in a position to control the content of a CME/CE activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.

Additionally, PER® and Purdue are required to resolve all COI.

Off-Label Disclosure and Disclaimer

This CME/CE activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME/CE activity is for continuing medical and nursing education purposes only, and is not meant to substitute for the independent clinical judgment of a physician relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER®, Purdue University or the companies that provided commercial support.

CME Provider Contact Information

Purdue University College of Pharmacy
601 Stadium Mall Drive, PUSH 336
West Lafayette, IN 47907
Local: 765-494-5457
Fax: 765-494-0802